Published Research and Presentations Publications Presentations Menu Publications Presentations Abstract TPS367: Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP 1601). KEYPAD ASCO GU 2021 - Virtual Meeting 11/02/2021 Craig Gedye, PhD, FRACP Abstract 6: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). TheraP ASCO GU 2021 - Virtual Meeting 11/02/2021 Michael S Hofman, FRACP, MBBS TheraP: A randomised phase 2 trial of Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel – initial results (ANZUP protocol 1603) TheraP ASCO 2020 - Virtual Meeting 29/05/2020 Hofman, M et al. Abstract TPS768: UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma. UNISoN ASCO GU 2020 13/02/2020 Craig Gedye, PhD, FRACP Abstract TPS602: Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301) BCG+MM ASCO GU 2020 13/02/2020 Elizabeth Liow, MBBS, FRACP Abstract TPS425: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) P3BEP ASCO GU 2020 13/02/2020 Shalini Subramaniam, MBBS Abstract 485: Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502) PCR MIB ASCO GU 13-15 February 2020 13/02/2020 Andrew Weickhardt, FRACP, MBBS Abstract TPS385: DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer DASL-HiCaP ASCO GU 2021 - Virtual Meeting 13/02/2020 Tamim Niazi, MD Health-related quality of life (HRQL) in a randomized phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial. ENZAMET ESMO 2019 Congress Poster Discussion 29/09/2019 Professor Martin Stockler Primary Efficacy Analysis Results From The SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double blind phase III trial led by the MRC CTU at UCL. SORCE ESMO 2019 Congress 28/09/2019 Professor Tim Eisen on behalf of the SORCE Trial Management Group Load More
Abstract TPS367: Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP 1601). KEYPAD ASCO GU 2021 - Virtual Meeting 11/02/2021 Craig Gedye, PhD, FRACP
Abstract 6: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). TheraP ASCO GU 2021 - Virtual Meeting 11/02/2021 Michael S Hofman, FRACP, MBBS
TheraP: A randomised phase 2 trial of Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel – initial results (ANZUP protocol 1603) TheraP ASCO 2020 - Virtual Meeting 29/05/2020 Hofman, M et al.
Abstract TPS768: UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma. UNISoN ASCO GU 2020 13/02/2020 Craig Gedye, PhD, FRACP
Abstract TPS602: Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301) BCG+MM ASCO GU 2020 13/02/2020 Elizabeth Liow, MBBS, FRACP
Abstract TPS425: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) P3BEP ASCO GU 2020 13/02/2020 Shalini Subramaniam, MBBS
Abstract 485: Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502) PCR MIB ASCO GU 13-15 February 2020 13/02/2020 Andrew Weickhardt, FRACP, MBBS
Abstract TPS385: DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer DASL-HiCaP ASCO GU 2021 - Virtual Meeting 13/02/2020 Tamim Niazi, MD
Health-related quality of life (HRQL) in a randomized phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial. ENZAMET ESMO 2019 Congress Poster Discussion 29/09/2019 Professor Martin Stockler
Primary Efficacy Analysis Results From The SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double blind phase III trial led by the MRC CTU at UCL. SORCE ESMO 2019 Congress 28/09/2019 Professor Tim Eisen on behalf of the SORCE Trial Management Group
